Clinical Development, Clinical Research and Hormones

Clinical Development

Clinical Research

Hormones

(Lopinavir + ritonavir) by Douglas Pharmaceuticals for Genital Warts (Condylomata Acuminata): Likelihood of Approval

Pharmaceutical Technology

FEBRUARY 24, 2023

(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Genital Warts (Condylomata Acuminata). Douglas collaborates with scientific researchers and external medical experts to advance clinical research. It operates in New Zealand, Fiji and the US.

Contract Manufacturing

Contract Manufacturing Dermatology Hormones Production

(Lopinavir + ritonavir) by Douglas Pharmaceuticals for Cervical Intraepithelial Neoplasia (CIN): Likelihood of Approval

Pharmaceutical Technology

FEBRUARY 24, 2023

(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Cervical Intraepithelial Neoplasia (CIN). Douglas collaborates with scientific researchers and external medical experts to advance clinical research. It operates in New Zealand, Fiji and the US.

Contract Manufacturing

Contract Manufacturing Dermatology Hormones Production

Join 21,000+

Insiders

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

Merck’s Keytruda flunks another prostate cancer test

pharmaphorum

JANUARY 26, 2023

Merck has said it will abandon the KEYNOTE-991 study of PD-1 inhibitor Keytruda (pembrolizumab) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) after it showed no benefit on either overall survival (OS) or radiographic progression-free survival (rPFS) when the data was analysed midway though.

Hormones

Hormones Trials FDA Approval Clinical Development

Lumos Pharma’s Patient-Centric Strategy for Rare Disease Drug Development

XTalks

JANUARY 23, 2024

Among these, rare pediatric diseases present unique challenges and opportunities for rare disease drug development. Pediatric growth hormone deficiency (PGHD) is one such condition, affecting a child’s growth and development.

Development

Development Hormones Drugs Trials

Amgen’s GLP-1 Drug MariTide Delivers Solid Weight Loss Results in Trial but Fails to Impress Analysts

XTalks

DECEMBER 5, 2024

Amgens randomized, double-blind, placebo-controlled Phase II study enrolled 592 adults with obesity or overweight conditions, defined by a body mass index (BMI) of 30 or 27, respectively, with at least one obesity-related comorbidity.

Trials

Trials Drugs Clinical Trials Clinical Trials

Lumos Pharma’s Commitment to Innovation in Rare Pediatric Growth Disorders

XTalks

MAY 23, 2024

For example, pediatric growth hormone deficiency (PGHD) affects approximately one in 3,500 to one in 10,000 children. Existing therapeutic options for PGHD consist of injectable formulations of recombinant human growth hormone (rhGH), administered subcutaneously either on a daily or weekly basis.

Clinical Trials

Clinical Trials Clinical Trials Hormones Trials

Amgen’s GLP-1 Drug MariTide Delivers Solid Weight Loss Results in Trial but Fails to Impress Analysts

XTalks

DECEMBER 5, 2024

Amgen’s randomized, double-blind, placebo-controlled Phase II study enrolled 592 adults with obesity or overweight conditions, defined by a body mass index (BMI) of ≥30 or ≥27, respectively, with at least one obesity-related comorbidity.

Trials

Trials Drugs Clinical Trials Clinical Trials

Cardiac Biomarkers in Cardiovascular Clinical Trials: Caveats and Considerations

XTalks

NOVEMBER 19, 2021

Natriuretic peptides like N-terminal (NT)-pro hormone B type natriuretic peptide (NT-proBNP), or BNP, are routinely used for acute and chronic heart failure. Full-Service Clinical Development. Watch the recent webinar by Medpace on cardiac biomarkers in CV trials featuring Dr. Januzzi.

Clinical Trials

Clinical Trials Clinical Trials Trials In-Vitro

Women’s Health Clinical Trials: Clinical Innovations, Opportunities and Considerations

XTalks

SEPTEMBER 11, 2024

In the webinar, Dr. Shah was joined by her colleague Dr. Rujin Ju, MD, MSCR, FACOG, Medical Director of the Medical Department, Women’s Health at Medpace, who discussed innovation in women’s health clinical research and FemTech — innovative technology-based products and services designed to address women’s health issues.

Clinical Trials

Clinical Trials Clinical Trials Trials Hormones

BioSpace Global Roundup, Oct. 15

The Pharma Data

OCTOBER 14, 2020

Priothera will use the funds to progress the clinical development of mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogeneic hematopoietic stem cell transplantation (HSCT) for treating AML. Axol Bioscience – Based in the U.K.,

Clinical Trials

Clinical Trials Clinical Trials Manufacturing In-Vivo

Diamyd Medical and Critical Path Institute announce data sharing collaboration to develop advanced drug development tools in type 1 diabetes

The Pharma Data

DECEMBER 15, 2020

It is funded by the world’s leading charities dedicated to diabetes research, JDRF, and Diabetes UK, guided by both organizations’ strong commitment to facilitate deep interrogation of consolidated community-wide trial data as a means to accelerate clinical research and therapeutic development for T1D.

Development

Development Insulin Drugs Clinical Trials

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

The Pharma Data

APRIL 4, 2023

Merck has the industry’s largest immuno-oncology clinical research program. The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient’s likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.

FDA Approval

FDA Approval Containment Hormones Dermatology

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) together With Chemotherapy surely Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative carcinoma Whose Tumors Express PD-L1 (CPS ?10)

The Pharma Data

SEPTEMBER 28, 2021

“Triple-negative carcinoma grows and spreads faster than other sorts of carcinoma and consequently features a worse prognosis,” said Dr. Vicki Goodman, vice chairman , clinical research, Merck Research Laboratories. Merck has the industry’s largest immuno-oncology clinical research program.

Hormones

Hormones Medicine Clinical Research Research

Clinical Research Informer

(Lopinavir + ritonavir) by Douglas Pharmaceuticals for Genital Warts (Condylomata Acuminata): Likelihood of Approval

(Lopinavir + ritonavir) by Douglas Pharmaceuticals for Cervical Intraepithelial Neoplasia (CIN): Likelihood of Approval

Trending Sources

Merck’s Keytruda flunks another prostate cancer test

Lumos Pharma’s Patient-Centric Strategy for Rare Disease Drug Development

Amgen’s GLP-1 Drug MariTide Delivers Solid Weight Loss Results in Trial but Fails to Impress Analysts

Lumos Pharma’s Commitment to Innovation in Rare Pediatric Growth Disorders

Amgen’s GLP-1 Drug MariTide Delivers Solid Weight Loss Results in Trial but Fails to Impress Analysts

Cardiac Biomarkers in Cardiovascular Clinical Trials: Caveats and Considerations

Women’s Health Clinical Trials: Clinical Innovations, Opportunities and Considerations

BioSpace Global Roundup, Oct. 15

Diamyd Medical and Critical Path Institute announce data sharing collaboration to develop advanced drug development tools in type 1 diabetes

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) together With Chemotherapy surely Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative carcinoma Whose Tumors Express PD-L1 (CPS ?10)

Stay Connected